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fi nally delivered across the basolateral 
membrane into the peritubular blood. 
However, this process has only a limited 
capacity. Th e ability of proximal tubular 
cells to degrade protein would most prob-
ably not be able to cope with a 50-fold 
increased load. However, it is unlikely 
that this load would reach the lysosomes, 
because the uptake machinery is satu-
rated previously. So how is the 50-fold 
increased load of albumin reabsorbed? 
Russo et al.8 suggest that the major part 
of reabsorption takes place by transcytosis 
of intact albumin (Figure 1), by contrast 
to the conclusions drawn to date in the 
large majority of studies.9 Th is concept 
would present the second shift  of para-
digm. However, this issue is supported by 
only a single fi gure of an apparently non-
systematic preliminary immunoelectron 
microscopic study. Th e suggested value 
of the GSC of albumin implies that the 
vast majority of the fi ltered albumin must 
be transcytosed intact. It is therefore sur-
prising that this transcytotic pathway was 
not detectable in previous studies. Th ere 
may be some transcytosis, but at the 
moment the evidence for a large rate of 
transcytotic reabsorption is rather weak. 
Transcytosis may explain how the limited 
degradation capacity is bypassed, but it 
does not explain how an eff ective uptake 
across the apical membrane occurs, in 
view of the saturated known receptors for 
albumin. Fluid-phase transcytosis is most 
probably not suffi  cient. Again, it is now 
of eminent importance to validate these 
data and verify or falsify the concept of 
substantial transcytosis.
We are confronted with a study apply-
ing a new and elegant technique to an 
old but very important issue, which up 
to now was never resolved unequivocally. 
Th e conclusions drawn attempt to shift  
two paradigms and are therefore of great 
potential relevance but require urgent 
validation. If these data can be verifi ed 
by others and also in other systems, we 
might gain a clearer view of the dark side 
of the fi lter.
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Measuring risk in end-stage 
renal disease: Is N-terminal pro 
brain natriuretic peptide a useful 
marker?
MH Rosner1
Natriuretic peptides are important in the maintenance of body volume 
homeostasis. There has been interest in utilizing the levels of these 
peptides to diagnose and prognosticate cardiovascular disease. In  end-
stage renal disease, the diagnostic utility of these peptides is limited. 
Madsen et al. report that levels of N-terminal pro brain natriuretic 
peptide (NT-proBNP) levels  offer important information on the risk of 
mortality in patients undergoing hemodialysis.
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Cardiovascular disease is the leading cause 
of mortality in patients with end-stage 
renal disease (ESRD). Although tradi-
tional risk factors such as elevated low-
density lipoprotein levels, hypertension, 
diabetes mellitus, and smoking account 
for a substantial percentage of the risk 
factor profi le in the general population, in 
patients with ESRD these traditional risk 
factors are limited in their ability to predict 
future events.1 Th us, attention has turned 
to the identifi cation of novel risk factors 
that can both refi ne prognosis and serve 
as potential targets of intervention. Th us, 
markers such as C-reactive protein, serum 
albumin, asymmetric dimethyl arginine, 
and numerous others have been shown to 
be independent predictors of death risk in 
the dialysis population.1 Th ose nontradi-
tional risk factors that can be shown to be 
causal are especially important, as they can 
signal both the presence and the severity 
of disease as well as serving as both guides 
and targets for therapy. In this context, 
the serum levels of natriuretic peptides 
in ESRD patients would seem an ideal 
candidate for such a causal risk factor for 
cardiovascular events.
Natriuretic peptides are a well-described 
family of hormones with a major role in 
sodium and body volume homeostasis.2 
Th e major members of this group of hor-
mones are atrial natriuretic peptide (ANP) 
and brain natriuretic peptide (BNP), along 
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with urodilatin. Th e synthesis and release 
of these peptides are stimulated by vari-
ous derangements in systemic blood pres-
sure, as well as increases in extracellular 
volume and sodium balance. Th eir major 
role is to induce natriuresis through their 
actions on renal hemodynamics and tubu-
lar function. In patients with normal renal 
function, release of BNP from the endo-
cardium is constitutive and is modulated 
by both pressure and volume overload 
of the ventricles.3 Th is is refl ected by the 
strong correlation between left  ventricu-
lar (LV) chamber size and LV end-diastolic 
pressure on the one hand, and BNP levels 
on the other.4 Overall, BNP levels provide 
a better index of LV mass and load than 
do ANP levels, and BNP has emerged as 
a superior biomarker to ANP for clinical 
applications involving heart failure and LV 
dysfunction.4 Th us, in vitro diagnostics for 
BNP and associated metabolites have been 
the focus for clinical applications.
In patients with ESRD, the role of BNP 
in inducing natriuresis is obviously limited. 
However, by virtue of the fact that serum 
levels of natriuretic hormones respond 
to increases in extracellular volume and 
are modulated by cardiac function, much 
interest has developed in using these hor-
mones as markers of volume status and 
cardiovascular risk in ESRD patients.
The synthesis and secretion of BNP 
follow a complex course, beginning with 
preproBNP, which is processed intra-
cellularly to proBNP, which is subse-
quently secreted by the cardiac myocyte 
(Figure 1).2,3 ProBNP then undergoes 
processing to yield the active hormone 
BNP (amino acids 79–108) or an inac-
tive fragment N-terminal (NT)-proBNP 
(amino acids 1–76) (released in a 1:1 
ratio). Commercial diagnostics for meas-
urement of either BNP or NT-proBNP 
are widely available and have been touted 
as a ‘white count’ for the diagnosis of 
congestive heart failure.5 However, the 
utility in this scenario is completely 
dependent on the pre-test probability of 
the presence of congestive heart failure, 
with the test being most useful in patients 
presenting with acute dyspnea of unclear 
etiology. Diagnostically, the utility of BNP 
and NT-proBNP is similar. However, there 
are diff erences between the two assays, 
as detailed in Table 1. Most importantly, 
NT-proBNP is cleared renally, and its 
levels show a stronger correlation with 
estimated glomerular fi ltration rate than 
do BNP levels.6 NT-proBNP is removed 
only to a small extent by hemodialysis, 
as is detailed both by Wahl et al.7 and by 
Madsen et al.8 (this issue). Furthermore, 
NT-proBNP has a longer half-life, and 
thus its levels may be more stable.
Initially, there was much interest in the 
use of BNP measurements in the assess-
ment of dry weight in ESRD patients. 
However, several studies demonstrated 
that BNP levels correlated better with 
LV function than with volume status.9 
Madsen and colleagues8 once again dem-
onstrate that NT-proBNP levels showed 
only a small decrement with dialysis and 
ultrafi ltration and that this fall did not 
correlate with volume removal or inter-
dialytic weight gain. More importantly, 
they demonstrate that NT-proBNP levels 
showed a strong negative correlation with 
LV function and a positive correlation 
with LV hypertrophy. Importantly, the 
majority of ESRD patients have elevated 
levels of either BNP or NT-proBNP, signi-
fying the high prevalence of abnormal LV 
function in this population. Th us, in bulk 
the data do not support the measurement 
of BNP in the determination of volume 
status or dry weight in ESRD patients. 
Furthermore, clinical correlation with 
BNP levels remains vitally important to 
ensure accurate diagnosis and therapeu-
tic maneuvers. For example, the fi nding 
of a markedly elevated BNP level in an 
asymptomatic ESRD patient may simply 
prompt a closer look at LV function and 
structure and not necessarily a change in 
dry weight.
The ability of BNP and NT-proBNP 
levels to predict cardiovascular events 
in ESRD patients has been extensively 
Figure 1 | Production of brain natriuretic peptide (BNP) and its metabolites.
preproBNP (134 amino acids)





Trimer of proBNP (36 kDA)
Table 1 | Features of brain natriuretic peptide (BNP) versus N-terminal (NT)-proBNP
Characteristic NT-proBNP BNP
Half-life 120 minutes 20 minutes
Hormonal activity No Yes
Clearance Renal Neutral endopeptidases
Clearance receptors
Increase with aging ++++ +
Correlation with eGFR –0.60 –0.20
Removal by hemodialysis ~10% ~30%
Approved cutoff value for CHF 
diagnosis (general population)
Age < 75: 125 pg/ml
Age ≥ 75: 450 pg/ml
100 pg/ml
eGFR, enhanced glomerular filtration rate; CHF, congestive heart failure.
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studied, and in this regard the fi ndings 
are similar to those in the general popu-
lation. In an early study, BNP levels were 
2.2-fold greater in ESRD patients who 
died than in survivors.10 Naganuma et 
al.11 prospectively studied a cohort of 164 
ESRD patients for 36 months aft er a single 
BNP level was measured. Th e hazard ratio 
for cardiac death in the group of patients 
with BNP levels greater than 700 pg/ml as 
compared with patients whose BNP levels 
were less than 200 pg/ml was 51.9. Zoc-
cali et al.12 also demonstrated that those 
ESRD patients with elevated BNP levels 
had a higher relative risk of death. Apple 
et al.13 demonstrated that NT-proBNP 
was a marker for predicting mortality 
risk in ESRD patients if tertile analysis 
was performed. The study by Madsen 
et al.8 expands on these studies. Over a 
2-year period, 109 prevalent ESRD 
patients had NT-proBNP measured before 
and aft er dialysis. By Kaplan-Meier analy-
sis, patients with either predialysis or post-
dialysis NT-proBNP levels above a median 
cutoff  value had signifi cantly higher total 
mortality, by approximately 40%. Fur-
thermore, multivariate Cox regression 
analysis revealed that only age and NT-
proBNP levels were predictive of mortal-
ity risk. More traditional risk factors such 
as cholesterol levels were not predictive. 
Receiver operating characteristic curves 
for NT-proBNP as a predictor of subse-
quent death gave an area under the curve 
of approximately 0.7. However, somewhat 
inexplicably, NT-proBNP predicted all-
cause mortality and not specifi cally cardi-
ovascular mortality. In part, this relates to 
a small number of cardiovascular events 
in the cohort and possibly to diffi  culties 
in classification of causes of mortality. 
A larger cohort of patients in multiple 
centers is required to better understand 
the relationship of NT-proBNP levels and 
cardiovascular outcomes.
How is this information likely to 
change our practice? Th e fact that ele-
vated natriuretic peptide levels in ESRD 
patients predict mortality fi ts with the 
known negative eff ects of LV dysfunc-
tion and hypertrophy on mortality, and 
natriuretic peptide levels may be a useful 
surrogate marker. An important question 
is the possible utility of serial monitor-
ing of BNP/NT-proBNP levels in ESRD 
patients. Do those patients with subse-
quent falls in BNP/NT-proBNP levels 
show decreased mortality? What inter-
ventions are successful in leading to sus-
tained reductions in BNP/NT-proBNP 
levels? Among patients with acute coro-
nary syndromes, those with persistently 
elevated BNP levels had higher mortality 
than those showing a decrease in BNP 
levels at 4 and 12 months post-event.14 
Intuitively, improved blood pressure and 
volume control should lead to improved 
LV function and lower BNP/NT-proBNP 
levels. These are important questions 
that need to be answered before routine 
measurement of these peptides can be 
recommended. It is important to point 
out that information regarding the use of 
biomarkers for risk stratifi cation is rarely 
relayed directly to the patient and will 
seldom change clinical practice unless 
specifi c therapy is being indicated on the 
basis of the information. Clinicians need 
biomarkers of risk that not only can iden-
tify those patients at high risk for morbid 
events but can also justify an interven-
tion. Th is is the next step in the evolution 
of natriuretic peptide measurements.
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